Skip to main content
NCBI home page
AAPS PharmSci logoLink to AAPS PharmSci
. 2001 Feb 12;3(1):80–91. doi: 10.1208/ps030107

Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication

Carole Lavigne 1,2, Jocelyn Yelle 1,2, Gilles Sauve 1,2, Alain R Thierry 3,4,✉
PMCID: PMC2751239  PMID: 11741258

Abstract

We evaluated a new approach to AIDS therapy by using combinations of oligodeoxynucleotides (ODNs), delivered with a lipid-based carrier system, that target different HIV viral genome sites. We identified some of the factors that seem to influence the effectiveness of a combination strategy in cell cultures including ODN concentrations, type of infection (acute vs chronic), backbone modification of the ODN, and the number of sequences. When delivered by the DLS carrier system, some advantages of using a combination of ODNs over treatment with only one ODN could be observed in acute infection assays but not in the chronic infection model. These results suggest that in the acute infection model, the 3 different antisense ODNs in the “cocktail” might block an early step of virus replication by combined inhibitory effects. Various combinations of phosphorothioate-modified (PS) and unmodified oligonucleotides delivered by the DLS system were compared for their antiviral activity in a long-term acute assay using HIV-1 (IIIB strain)-infected MOLT-3 cells. The most effective combination had 3 phosphorothioate antisense ODNs: Srev, SDIS, and SPac (>99% inhibition at 100 pM). However, the additive effect determined when using ODN combinations was rather low, revealing the high level of nonsequence specificity in HIV-1 cell culture models. Data illustrated the high sequence nonspecific activity of ODNs, especially when comparing activity of antisense ODNs with activity of random control sequence ODNs. The latter exhibited an inhibitory effect similar to that of antisense ODNs under our experimental conditions. Nevertheless, we demonstrated that it is possible to achieve high anti-HIV activity by using, in combination, picomolar range concentrations of antisense oligonucleotides complexed to a lipid-based carrier system such as the DLS system, without increasing cell toxicity.

KeyWords: antisense, oligonucleotides, HIV, drug delivery

References

  • 1.Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutics agents: Is the bullet really magical? Science. 1993;261:1004–1012. doi: 10.1126/science.8351515. [DOI] [PubMed] [Google Scholar]
  • 2.Zhang R, Yan J, Shahinian H, et al. Pharmacokinetics of an antihuman immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther. 1995;58:44–53. doi: 10.1016/0009-9236(95)90071-3. [DOI] [PubMed] [Google Scholar]
  • 3.Yamaguchi K, Papp B, Zhang D, Ali AN, Agrawal S, Byrn RA. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1997;13:545–554. doi: 10.1089/aid.1997.13.545. [DOI] [PubMed] [Google Scholar]
  • 4.Akhtar S, Rossi JJ. Anti-HIV therapy with antisense oligonucleotides and ribozymes: Realistic approaches of expensive myths? J. Antimicrob Chemother. 1996;38:159–165. doi: 10.1093/jac/38.2.159. [DOI] [PubMed] [Google Scholar]
  • 5.Matsukura M, Zon G, Shinozuka K, et al. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphotothioate oligodeoxynucleotide against rev (artitrs) in chronically infected cells. Proc Natl Acad Sci U S A. 1989;86:4244–4248. doi: 10.1073/pnas.86.11.4244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kinchington D, Galpin S, Jaroszewski JW, Ghosh K, Subasinghe C, Cohen JS. A comparison of gag. pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antivir Res. 1992;17:53–62. doi: 10.1016/0166-3542(92)90090-R. [DOI] [PubMed] [Google Scholar]
  • 7.Lisziewicz J, Sun D, Weichold FF, et al. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sci U S A. 1994;91:7942–7946. doi: 10.1073/pnas.91.17.7942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Anazodo MI, Wainberg MA, Friesen AD, Wright JA. Sequence-specific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type I genome. J Virol. 1995;69:1794–1801. doi: 10.1128/jvi.69.3.1794-1801.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature. 1985;313:277–284. doi: 10.1038/313277a0. [DOI] [PubMed] [Google Scholar]
  • 10.Skripkin E, Paillart J-C, Marquet R, Ehresmann B, Ehresmann C. Identification of the primary site of the human immunodeficiency virus type 1 RNA dimerization in vitro. Proc Natl Acad Sci U S A. 1994;91:4945–4949. doi: 10.1073/pnas.91.11.4945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Muriaux D, Girard P-M, Bonnet-Mathonière B, Paoletti J. Dimerization of HIV-1 Lai RNA at low ionic strength. J Biol Chem. 1995;270:8209–8216. doi: 10.1074/jbc.270.14.8209. [DOI] [PubMed] [Google Scholar]
  • 12.Kim S-G, Hatta T, Tsukahara S, et al. Antiviral effect of phosphorothioate oligodeoxyribonuleotides complementary to human immunodeficiency virus. Bioorg & Med Chem. 1995;3:49–54. doi: 10.1016/0968-0896(94)00142-P. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.McBride MS, Panganiban AT. The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures. J Virol. 1996;70:2963–2973. doi: 10.1128/jvi.70.5.2963-2973.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lever A, Gottlinger H, Haseltine W, Sodroski J. Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol. 1989;63:4085–4087. doi: 10.1128/jvi.63.9.4085-4087.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Aldovini A, Young RA. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J Virol. 1990;64:1920–1926. doi: 10.1128/jvi.64.5.1920-1926.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Agrawal S, Tang JY. GEM*91—An antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev. 1992;2:261–266. doi: 10.1089/ard.1992.2.261. [DOI] [PubMed] [Google Scholar]
  • 17.Agrawal S. GEM 91: Antisense oligodeoxynucleotide phosphorothioate inhibitor of HIV-1 replication. Drugs of the Future. 1995;20:344–351. [Google Scholar]
  • 18.Lavigne C, Thierry AR. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system. Biochem Biophys Res Commun. 1997;237:566–571. doi: 10.1006/bbrc.1997.7191. [DOI] [PubMed] [Google Scholar]
  • 19.Popovic M, Read-Conole E, Gallo RC. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet. 1984;2:1472–1473. doi: 10.1016/S0140-6736(84)91666-0. [DOI] [PubMed] [Google Scholar]
  • 20.Popovic M, Samgadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984;224:497–500. doi: 10.1126/science.6200935. [DOI] [PubMed] [Google Scholar]
  • 21.Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC. Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci U S A. 1995;92:9742–9746. doi: 10.1073/pnas.92.21.9742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Thierry AR, Rabinovich P, Peng B, Bryant JL, Gallo RC. Characterization of liposome-mediated gene delivery expression, stability and pharmacokinetics of plasmid DNA. Gene Ther. 1997;4:226–237. doi: 10.1038/sj.gt.3300350. [DOI] [PubMed] [Google Scholar]
  • 23.Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods. 1988;20:309–321. doi: 10.1016/0166-0934(88)90134-6. [DOI] [PubMed] [Google Scholar]
  • 24.Jendis J, Strack B, Volkmann S, Boni J, Mölling K. Inhibition of replication of fresh HIV type 1 patient isolates by a polypurine tract-specific self-complementary oligodeoxynucleotide. AIDS Res Hum Retroviruses. 1996;12:1161–1168. doi: 10.1089/aid.1996.12.1161. [DOI] [PubMed] [Google Scholar]
  • 25.Zelphati O, Imbach JL, Signoret N, Zon G, Rayner B, Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. 1994;22:4307–4314. doi: 10.1093/nar/22.20.4307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Weichold FF, Lisziewicz J, Zeman RA, et al. Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells. AIDS Res Hum Retroviruses. 1995;11:863–867. doi: 10.1089/aid.1995.11.863. [DOI] [PubMed] [Google Scholar]
  • 27.Crooke MR. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Design. 1991;6:609–646. [PubMed] [Google Scholar]
  • 28.Stein CA. Phosphorothioate antisense oligodeoxynucleotides questions of specificity. Trends Biotechnol. 1996;14:147–149. doi: 10.1016/0167-7799(96)20006-X. [DOI] [PubMed] [Google Scholar]
  • 29.Tamamoto T, Yamamoto S, Kataoka T, Tokunaga T. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev. 1994;4:119–122. doi: 10.1089/ard.1994.4.119. [DOI] [PubMed] [Google Scholar]
  • 30.Krieg A, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546–549. doi: 10.1038/374546a0. [DOI] [PubMed] [Google Scholar]
  • 31.White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. J Clin Invest. 2000;106:929–934. doi: 10.1172/JCI11325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Gareth JV, Agrawal S, Byrn RA. Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors. Antivir Res. 1998;38:63–73. doi: 10.1016/S0166-3542(98)00004-7. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSci are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES